Oracle and ObvioHealth come together for ‘tight integration’ of data in APAC DCTs
Global virtual research organization (VRO), ObvioHealth, in alliance with Oracle will focus on integration of diverse data sets to bolster decentralized clinical trials (DCTs) and move therapies to market faster.
Through this alliance the eConsent, eCOA, and ePRo capabilities of ObvioHealth’s newly announced DCT platform, ObvioGo, will fully integrate into the Oracle Clinical One Cloud Service. This integration will enable rapid collection, integration, and analysis of multi-source data collected from sites, patients, devices and labs.
Ivan Jarry, CEO of ObvioHealth, told us that both the VRO and Oracle were “looking to blend their respective clinical trial solutions to create a more complete ecosystem to address today’s evolving clinical research world.”
The combined solution created via the alliance leverages a combination of data formats and direct API-based integration to exchange data, configure, and map the data as it flows between systems, Jarry explained.
By removing the process of mapping data, this solution, according to Jarry, will help create shorter study implementation timelines. “This tight integration not only allows for flow of data in near real time, it also streamlines and coordinates the study configuration process,” said Jarry.
As ObvioHealth is focused on DCTs which collect data from a lot of different sources, the partnership will provide the VRO a unified environment to bring all the data collected from DCTs together.
He added, that the combination of these integrated approaches with a focus on leveraging the operational and analytical strengths of each organizations systems provides for a comprehensive solution for both hybrid and full virtualized clinical trials.
“Having a solution that aggregates all these sources while facilitating tried and true data management practices is critical to the delivery of quality outcomes,” said Jarry.
Work in APAC can lead to richer insights and “unlock a wealth of possibilities in APAC,” according to Jarry. He stated that the data that can be collected in APAC can help industry stakeholders identify disease correlations and longitudinal trends which can led to uncovering new indications for treatment.
Henry McNamara, SVP and general manager at Oracle Health Solutions stated, “Access to data is the cornerstone of moving therapies from clinical trials to available therapies, and trial sponsors in APAC are increasingly looking to more decentralized models to be able to increase trial equity, access, and data availability.”
Jarry explained that ObvioHealth has a large footprint in the Asia Pacific (APAC) region and Oracle is a partner that is aligned with that target market. ObvioHealth is one of the first VRO’s to conduct fully virtual DCTs in the region.
There is an opportunity for the alliance to grow outside of the region as the partnership between Oracle and the VRO evolves.
